Regulatory Pharmacovigilance in the EU

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 185-198

  Bahri, Priya ^a   Tsintis, Panos ^a   Waller, Patrick C ^b  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b NONE

Author keywords

Adverse drug reactions (ADRs) detection; EMEA and Pharmacovigilance Working Party (PhVWP); European Agency for the Evaluation of Medicinal Products (EMEA); European Economic Area (EEA); Regulatory pharmacovigilance in European Union (EU)

Indexed keywords

EID: 84864286910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch14     Document Type: Chapter

References (25)

1. Commission Regulation (EC) No. 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products granted by a competent authority of a Member State. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L159, 27/06/2003, pp. 1-23.
2. Commission Regulation (EC) No. 1085/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products falling within the scope of Council Regulation(EEC)No. 2309/93. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L159, 27/06/2003, pp. 24-45.
3. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, 022, pp. 3-12.
4. Council Directive 75/319/EEC of 20May1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products as amended (1993) In Pharmaceutical Legislation: Medicinal Products for Human Use, Office for Official Publications of the European Communities, Luxembourg (1998), pp. 41-63.
5. Council Directive 93/39/EEC of 14 June 1993 amending Directives 65/65, 75/318/EEC and 75/319/EEC in respect of medicinal products. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L 214, pp. 22-30.
6. Council Regulation (EEC) No. 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products forhumanand veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L 214, pp. 1-21.
7. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use as amended. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L 311, 28/11/2004, pp. 67-128.
8. EEA Joint Committee Decision No. 74/1999. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, 9 November 2000, pp. 65-6.
9. EMEA/CHMP Working Group with Patient Organisations (2005) Outcome of Discussions: Recommendations and Proposals for Action. London: EMEA. http://www.emea. eu.int/pdfs/human/patientgroup/14947904en.pdf.
10. European Commission (2006) Volume 9 A of the Rules Governing Medicinal Products in the European Union. In the process of publicationon http://ec.europa.eu/enterprise/ pharmaceuticals/index_en.htm.
11. European Medicines Agency (2004) EudraVigilance Website. http://www.eudravigilance.org/highres.htm.
12. European Medicines Agency (2005) EMEA Website. http:// www.emea.eu.int.
13. European Union institutions and other bodies (2005) European Union Institutions and Other Bodies Website. http://europa.eu.int/institutions/index_en.htm.
14. Felix RH, Ive FA, Dahl MCG (1974) 'Cutaneous and ocular reactions to practolol'. British Medical Journal 4: 321-4.
15. Herings RMC (1993) PHARMO: A Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands [Dissertation]. Utrecht: Universiteit Utrecht.
16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2005) ICH Website. Geneva: ICH Secretariat. http://www.ich.org.
17. Jefferys DB, Leakey D, Lewis J et al. (1998) New active substances authorized in the United Kingdom between 1972 and 1994. British Journal of Clinical Pharmacology 45: 151-6.
18. Olsson S (ed.) (1999) National Pharmacovigilance Systems. Uppsala: The Uppsala Monitoring Centre-WHO Collaborating Centre for International Drug Monitoring.
19. Regulation (EEC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. In Official Journal of the European Communities, Office for Official Publications of the European Communities, Luxembourg, L 136, 30/04/2004, pp. 1-33.
20. Stephens T, Brynner R (2001) Dark Remedy: The Impact of Thalidomide and its Revival Vital Medicine. New York: Perseus.
21. Tsintis P, LaMache E (2004) CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Safety 27: 509-17.
22. Uppsala Monitoring Centre (2005) UMC Website. http://www.who-umc.org.
23. Waller PC, Evans SJ (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Safety 12: 17-29.
24. Waller PC, Coulson RA, Wood SM (1996) Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol and Drug Safety 5: 363-75.
25. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350: 1097-9.